高级检索
    李晨, 曹爱红. 载药微球经动脉化疗栓塞术联合阿帕替尼及PD-1单抗治疗中晚期肝癌的疗效及安全性分析[J]. 徐州医科大学学报, 2023, 43(6): 404-409. DOI: 10.3969/j.issn.2096-3882.2023.06.003
    引用本文: 李晨, 曹爱红. 载药微球经动脉化疗栓塞术联合阿帕替尼及PD-1单抗治疗中晚期肝癌的疗效及安全性分析[J]. 徐州医科大学学报, 2023, 43(6): 404-409. DOI: 10.3969/j.issn.2096-3882.2023.06.003
    shu
    LI Chen, CAO Aihong. Effectiveness and safety of DEB-TACE combined with apatinib and anti-PD-1 antibody in patients with moderate and advanced liver cancer[J]. Journal of Xuzhou Medical University, 2023, 43(6): 404-409. DOI: 10.3969/j.issn.2096-3882.2023.06.003
    Citation: LI Chen, CAO Aihong. Effectiveness and safety of DEB-TACE combined with apatinib and anti-PD-1 antibody in patients with moderate and advanced liver cancer[J]. Journal of Xuzhou Medical University, 2023, 43(6): 404-409. DOI: 10.3969/j.issn.2096-3882.2023.06.003
    shu

    载药微球经动脉化疗栓塞术联合阿帕替尼及PD-1单抗治疗中晚期肝癌的疗效及安全性分析

    Effectiveness and safety of DEB-TACE combined with apatinib and anti-PD-1 antibody in patients with moderate and advanced liver cancer

      摘要
    • 摘要: 目的 探讨载药微球经动脉化疗栓塞术(DEB-TACE)联合阿帕替尼及PD-1单抗治疗中晚期肝癌的疗效及安全性。方法 回顾性分析2019年6月-2021年2月在徐州医科大学附属徐州市立医院行DEB-TACE联合阿帕替尼、PD-1单抗治疗的中晚期肝癌患者,比较治疗前后患者肝功能及肿瘤标志物的变化,统计客观缓解率(ORR)、疾病控制率(DCR)、无进展生存期(PFS)、总生存期(OS)以及治疗相关不良事件。结果 共20例患者纳入该研究,治疗后1个月、3个月、6个月患者的ORR分别为70%、60%、40%,DCR分别为90%、80%、75%。截至随访,患者中位PFS为9.0个月(95%CI 7.1~11.0个月),中位OS为11.0个月(95%CI 8.3~13.7个月)。与术前相比,患者术后3 d转氨酶及胆红素升高,白蛋白及甲胎蛋白降低。治疗过程中最常见的不良反应为手足综合征、高血压。结论 DEB-TACE联合阿帕替尼及PD-1单抗治疗中晚期肝癌患者安全有效。

       

      Abstract: Objective To evaluate the clinical effectiveness and safety of DEB-TACE combined with apatinib and anti-programmed cell death-1 (PD-1) antibody in patients with moderate and advanced liver cancer.Methods Patients with moderate and advanced liver cancer who underwent drug-eluting bead transarterial chemoembolization (DEB-TACE) plus apatinib and PD-1 monoclonal antibody in the Affiliated Xuzhou Municipal Hospital of Xuzhou Medical University from June 2019 to February 2021 were enrolled, and their clinical data were retrospectively analyzed. Their hepatic function and tumor marker changes before and after treatment were compared. The objective response rate (ORR), disease control rate (DCR), progression-free survival (PFS), overall survival (OS), and treatment-related adverse events (TRAEs) were recorded.Results There were totally 20 patients included in this study. At postoperative 1, 3, and 6 months, the ORR was 70%, 60%, 40% respectively, while the DCR was 90%, 80%, and 75%, respectively. The median PFS and OS was 9.0 months(95%CI 7.1-11.0 months) and 11.0 months(95%CI 8.3-13.7 months), respectively. Compared with those before treatment, the patients showed up-regulated levels of ALT, AST, and TBIL, and down-regulated levels of ALB and AFP. The most common adverse events were hand-foot syndrome and hypertension.Conclusions The combination of DEB-TACE, apatinib and anti-PD-1 antibody is effective and safe for patients with moderate and advanced liver cancer.

       

      • HTML全文
      • 参考文献(21)
      • 相关文章
      • 施引文献
    • 资源附件(0)

    /

    返回文章
    返回